Infectious Keratitis
13
2
2
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.7%
1 terminated out of 13 trials
88.9%
+2.4% vs benchmark
8%
1 trials in Phase 3/4
25%
2 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (13)
Effect of Sodium Chloride 5% Solution as an Adjuvant Treatment With Antimicrobial Therapy in the Treatment of Bacterial Infectious Keratitis
Cross-linking for Corneal Ulcers Treatment Trial
Use of a New Method for the Microbiological Diagnosis of Severe Corneal Infection
The Role of OmniLenz® in the Treatment of Small Corneal Perforations Secondary to Exposure Keratitis in ICU Patients
Non-invasive Diagnostics of Microbial Keratitis
Microbiological Diagnosis of Infectious Keratitis to Pathogenic Fastidious Germs
Cross-linking as Treatment in Infectious Keratitis
Investigation of the Microbiome of the Cornea in Microbial Keratitis
Crosslinking in Infectious Keratitis
Association Between SNP of SP-D and Susceptibility and Prognosis of Infectious Keratitis
Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis
Cross Linking for Treatment of Corneal Infection
Collagen Cross-linking in Infectious Keratitis Trial